Safety and humoral immunogenicity of COVID-19 vaccine against SAR-CoV2 wild type and Omicron variant in patients with solid cancer

Faculty of Medicine, Chiang Mai University0 个研究点目标入组 110 人开始时间: 2023年5月10日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. age 18 years or above
•2. Has an appointment to receive vaccine against SAR-CoV2
•3. Confirmed diagnosis of solid tumor by pathology or imaging with any stages, treatments and responses after treatment that include complete remission disease within 1 year
•4. Life expectancy is more than 6 months at the time receiving first dose of vaccine

•1. Previously diagnosed COVID-19 in the past 90 days
•2. High-risk epidemiology history within 14 days before enrolment e.g. close contact with index cases or visiting/ living in outbreak area
•3. Receive blood products, blood components, or immunoglobulin within the past 90 days
•4. Receive live attenuated vaccine in the past 28 days
•5. Receive inactivated or subunit vaccines in the past 14 days
•6. Women in lactation, pregnancy, or planned pregnancy during the study period
•7. Known allergy to any vaccine component
•8. Has signs and symptoms of active skin infection at injection site
•9.Known history of HIV infection
•10.Receive immunosuppressive drug
•11. Has uncontrolled medical illness that include cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, and neurological disease

发起方